Endocrine Therapies in Breast Cancer

— —

Aman U. Buzdar (Professor of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, USA)

Endocrine Therapies in Breast Cancer

Aman U. Buzdar (Professor of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, USA)

$48.95

Paperback

Not in-store but you can order this
How long will it take?

Availability Information

We source books from suppliers in Australia and overseas. For books we don't currently have in stock, the time it takes to get them from our suppliers can vary widely - from a few days to a few months - so we check each book with each supplier to determine the expected time it will take to be supplied to us.

We then advise you accordingly. If the time taken to get any book is too long for you, you can let us know and we will cancel or adjust your order, and refund as required.

To find out the anticipated arrival time for specific items prior to ordering, please contact us by phone or email:

Phone +61 2 9264 3111, or 1800 4 BOOKS (1800 4 26657) if outside Sydney:
option 1 Abbey's Bookshop (Crime, History, Science, Kids & more) • info@abbeys.com.au
option 2 Language Book Centre (ESL & Foreign Languages) • language@abbeys.com.au
option 3 Galaxy Bookshop (Sci-fi, Fantasy, Romance, Graphic Novels) • sf@galaxybooks.com.au

QTY:

English

Oxford University Press
18 October 2007

Oncology; Pharmacology; Nursing

Series: Oxford Oncology Library

Breast cancer is one of the leading causes of cancer mortality in women worldwide, and the risk of disease recurrence continues despite improvements in screening and treatment. For patients with hormone receptor-positive breast cancer, some form of endocrine therapy is central to the management of their disease. Tamoxifen has long been the mainstay of endocrine therapy in this group of patients. However, there is mounting evidence showing that the aromatase inhibitors are able to reduce overall oestrogen levels and appear to be better tolerated over a long term than tamoxifen. New and emerging indications for the aromatase inhibitors are providing clinicans (and patients) with alternative treatment options with differing side effect profiles.

Part of the Oxford Oncology Library, this pocketbook will summarise the latest evidence-based and practical information on the use of endrocrine therapies in the management of breast cancer (early stage, metastatic disease, and prevention of disease). With contributions from leading oncologists from the MD Anderson Cancer Center, the book covers the range of endocrine therapies currently available to clinicians including ovarian ablation, anti-estrogens, aromatase inhibitors, fulvestrant, progestins, androgens, and combination endocrine and chemotherapy. The book also includes useful chapters on the identification and optimal selection of patients for endocrine therapy as well as the role of endocrine treatments in the prevention of breast cancer. This book will serve as an invaluable reference for all health care professionals involved in the management of patients with breast cancer.

Edited by: Aman U. Buzdar (Professor of Breast Medical Oncology University of Texas MD Anderson Cancer Center Houston USA)
Imprint: Oxford University Press
Country of Publication: United Kingdom
Dimensions: Height: 179mm, Width: 99mm, Spine: 6mm
Weight: 112g
ISBN: 9780199218141
ISBN 10: 0199218145
Series: Oxford Oncology Library
Pages: 130
Publication Date: 18 October 2007
Audience: Professional and scholarly , Undergraduate
Format: Paperback
Publisher's Status: Active